American Thoracic Society

Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference

Retrieved on: 
Wednesday, March 27, 2024
Conference, ATS, Physicalism, SAN, University, American Thoracic Society, Abstract, Poster, Therapy

SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced that the Company will present four scientific posters at the upcoming 2024 American Thoracic Society (ATS) International Conference, taking place in San Diego, California from May 17-22, 2024.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced that the Company will present four scientific posters at the upcoming 2024 American Thoracic Society (ATS) International Conference, taking place in San Diego, California from May 17-22, 2024.
  • The following abstracts are posted on ATS 2024’s online itinerary planner.
  • Presenter: Jonathan G. Goldin, M.D., Ph.D., Professor of Radiology, Medicine and Biomedical Physics at the David Geffen School of Medicine at the University of California, Los Angeles
    Pliant was also selected for a featured oral presentation as part of the ATS 2024 Mini Symposiums program.
  • Posters will be available to view during the ATS Conference, Sunday, May 19 - Wednesday, May 22.

Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference

Retrieved on: 
Wednesday, March 27, 2024
Conference, ATS, Patient, Inhalation, American Thoracic Society, Orthostatic hypertension, Therapy, Safety, Pharmaceutical industry

The presentation will provide baseline characteristics from patients enrolled in the dose-ranging Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT), a Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multi-national trial evaluating the safety and efficacy of AV-101 in adults with pulmonary arterial hypertension.

Key Points: 
  • The presentation will provide baseline characteristics from patients enrolled in the dose-ranging Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT), a Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multi-national trial evaluating the safety and efficacy of AV-101 in adults with pulmonary arterial hypertension.
  • “We look forward to presenting baseline characteristics of the Phase 2b portion of the IMPAHCT trial in our poster presentation at the upcoming ATS conference in May,” said Tim Noyes, Chief Executive Officer at Aerovate Therapeutics.
  • “These data will provide insight into the IMPAHCT patient population as we continue Phase 3 trial recruitment globally and expect to present top line Phase 2b data in June.”
    Details for the poster presentation are as follows:
    Abstract: Baseline characteristics from the IMPAHCT trial of AV-101, inhaled imatinib, in subjects with pulmonary arterial hypertension
    The poster abstract is available now on the 2024 ATS website.
  • The abstract includes data from 147 patients, and the poster presentation on May 21st will include baseline characteristics for all 202 Phase 2b patients.

Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference

Retrieved on: 
Tuesday, April 9, 2024
MB, NHS foundation trust, Conference, ATS, NIHR, University of Manchester, University, Doctor of Philosophy, Respiratory Medicine, American Thoracic Society, Chronic cough, FRCP, IPF, Idiopathic pulmonary fibrosis, RCC, Therapy

NEW HAVEN, Conn., April 9, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that data from the Phase 2 CANAL trial will be presented at the American Thoracic Society (ATS) 2024 International Conference being held in San Diego, CA, from May 17-22. The presentation will take place on May 19th.

Key Points: 
  • NEW HAVEN, Conn., April 9, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that data from the Phase 2 CANAL trial will be presented at the American Thoracic Society (ATS) 2024 International Conference being held in San Diego, CA, from May 17-22.
  • The presentation will take place on May 19th.
  • Presenter: Jacky Smith, MB, ChB, FRCP, PhD, Professor of Respiratory Medicine at the University of Manchester, and an Honorary Consultant at Manchester University NHS Foundation Trust.
  • Director of the NIHR Manchester Clinical Research Facility, Respiratory Theme Lead in the NIHR Manchester Biomedical Research Centre and an NIHR Senior Investigator.

Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights

Retrieved on: 
Monday, March 25, 2024
Research, Conference, ATS, Actelion, Patent, Intellectual, Patient, Inhalation, Travel, Merck, Sale, American Thoracic Society, Investment, Clinical trial, Merck & Co., Therapy, PAH, Pharmaceutical industry

Cash, cash equivalents and short-term investments totaled $122.4 million as of December 31, 2023, compared to $135.2 million as of September 30, 2023.

Key Points: 
  • Cash, cash equivalents and short-term investments totaled $122.4 million as of December 31, 2023, compared to $135.2 million as of September 30, 2023.
  • The decrease was primarily driven by operational costs for the three-month period ended December 31, 2023.
  • Net loss: Net loss for the year ended December 31, 2023 was $75.5 million as compared to $51.5 million for the year ended December 31, 2022.
  • Net loss included stock-based compensation expense of $11.9 million and $5.5 million for the years ended December 31, 2023 and December 31, 2022, respectively.

RS BioTherapeutics Selected for Presentation at American Thoracic Society’s 2024 Respiratory Innovation Summit

Retrieved on: 
Monday, March 18, 2024
ATS, Science, Medicine, American Thoracic Society, Chronic obstructive pulmonary disease, Death, Idiopathic pulmonary fibrosis, IPF, COPD, Idiopathic disease, Government

CUMBERLAND, Md., March 18, 2024 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to develop life-changing medicines for the millions of people suffering from diseases characterized by pulmonary inflammation, is pleased to announce that its submission has been selected for a poster presentation at the 2024 Respiratory Innovation Summit hosted by the American Thoracic Society (ATS).

Key Points: 
  • CUMBERLAND, Md., March 18, 2024 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to develop life-changing medicines for the millions of people suffering from diseases characterized by pulmonary inflammation, is pleased to announce that its submission has been selected for a poster presentation at the 2024 Respiratory Innovation Summit hosted by the American Thoracic Society (ATS).
  • The summit will be held at the Manchester Grand Hyatt in San Diego, California on Friday, May 17 and Saturday, May 18.
  • The ATS 2024 Respiratory Innovation Summit will unite the innovators, investors, clinicians, and advocacy groups who are leading the charge to create powerful new treatments for deadly and crippling diseases of the lungs and airways.
  • Commenting on RS BioTherapeutics’ selection, the company’s Chief Medical Officer, Dr. Michelle L. Shuffett said, “It is a distinct honor to be among the companies selected for a poster presentation at the Respiratory Innovation Summit.

aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update

Retrieved on: 
Thursday, March 14, 2024
PDT, Research, Conference, Interest, ATS, Biologics license application, Patient, SAN, Howard University, Knowledge, EAP, ATyr Pharma, EDT, NRP2, American Thoracic Society, Downstream, Investment, Clinical trial, Small RNA, Neuropilin, Myelocyte, Safety, Sarcoidosis, Immune system, FGF2, FGFR4, BLA, Pharmaceutical industry

SAN DIEGO, March 14, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced fourth quarter and full year 2023 results and provided a corporate update.

Key Points: 
  • SAN DIEGO, March 14, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced fourth quarter and full year 2023 results and provided a corporate update.
  • Based on current enrollment projections, the Company anticipates completing enrollment in the study in the second quarter of 2024.
  • Interested parties may access the call by registering here in order to obtain a dial in, personalized passcode and webcast information.
  • Links to a live audio webcast and replay may be accessed on the aTyr website Events page at: http://investors.atyrpharma.com/events-and-webcasts .

Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors

Retrieved on: 
Tuesday, March 12, 2024
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Pulmonary hypertension, Health care, Artificial intelligence, American Thoracic Society, Whitehead Institute, Lung transplantation, Idiopathic pulmonary fibrosis, Medical director, Biomedical Research, Pulmonology, Capital Group Companies, Gossamer, Partnership, American College, Wellesley College, American studies, Commerce, Creative, Medical education, Biomedicine, Latin American studies, International Society, Putnam Investments, MNTN, University, Senior, House, Publication, Portfolio manager, FDA, Internal medicine, Entrepreneurship, Lord Abbett, MIT, Capital, Bloomberg, GOSS, Orthostatic hypertension, IPF, Initial public offering, Partner, Idiopathic disease, PAH, Pharmaceutical industry

Skye Drynan is the Founder, CEO and Creative Director of House of Skye, Ltd., and a former Partner and Senior BioPharma Analyst at Capital Group.

Key Points: 
  • Skye Drynan is the Founder, CEO and Creative Director of House of Skye, Ltd., and a former Partner and Senior BioPharma Analyst at Capital Group.
  • Ms. Drynan joins the Board with an extensive background in finance, investment, and entrepreneurship, specializing in the biotechnology industry.
  • “The addition of Dr. Nathan to our Board signifies a pivotal moment in Gossamer’s evolution,” said Faheem Hasnain, Co-Founder, Chairman and CEO of Gossamer Bio.
  • Ms. Drynan is the Founder, CEO and Creative Director of House of Skye, Ltd., which she founded in 2016.

The Inner Circle acknowledges Antony Jackson Arumairaj, MD as a Top Pinnacle Physician

Retrieved on: 
Tuesday, April 2, 2024
College, Research, American Medical Association, Royal Australasian College, Internal medicine, Critical Care Medicine (journal), Patient, Publishing, Emergency medicine, MD, American College of Physicians, Mentorship, Royal college, American Thoracic Society, Society, Bachelor, American College, Stanley Medical College, Internship, Multimedia, Health, Inner circle, Teaching, Nursing

JERSEY CITY, N.J., April 2, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Antony Jackson Arumairaj, MD is acknowledged as a Top Pinnacle Physician for his contributions as a Distinguished Internal Medicine Specialist.

Key Points: 
  • JERSEY CITY, N.J., April 2, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Antony Jackson Arumairaj, MD is acknowledged as a Top Pinnacle Physician for his contributions as a Distinguished Internal Medicine Specialist.
  • In this capacity, he not only provides exceptional patient care but also plays a pivotal role in teaching and mentoring medical students.
  • His dedication to the well-being of his patients and commitment to medical education make him a valuable asset to the healthcare community.
  • He aims to complete his Pulmonary Critical Care fellowship and become an Attending Physician at a university hospital.

Going Beyond ATS/ERS 2019 Guidelines for Your Respiratory Clinical Trials, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, March 27, 2024
American Thoracic Society, Doctor of Philosophy, EDT, ATS, ERS, Drug development

TORONTO, March 27, 2024 /PRNewswire-PRWeb/ -- Join this insightful webinar in which the expert speakers will explore the evolution of data quality assessments in respiratory drug development. Historically, adherence to enforced spirometry standards from the American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines has been the acceptable measure of high-quality data. However, despite refinements made in 2019 to address limitations in the historical standards, inconsistencies and aberrant treatment effects remain a persistent challenge, raising concerns over data accuracy.

Key Points: 
  • The featured speakers will discuss the limitations of traditional adherence to the American Thoracic Society (ATS)/European Respiratory Society (ERS)-enforced spirometry standards.
  • They will expore how improved data quality can accelerate drug development, reduce costs and enable better development decisions for personalized medicine.
  • TORONTO, March 27, 2024 /PRNewswire-PRWeb/ -- Join this insightful webinar in which the expert speakers will explore the evolution of data quality assessments in respiratory drug development.
  • Clario, a leader in clinical research and technology, has been initiating a more focused approach to ensure respiratory data accuracy within clinical trials.

Data from Brainomix's Collaboration with AstraZeneca Shows its AI-Powered e-Lung Better Identifies Lung Fibrosis Patients at Risk of Decline

Retrieved on: 
Wednesday, March 27, 2024
AJRCCM, Medical research, ILD, AstraZeneca, ATS, Survival, Data science, Critical Care Medicine (journal), Partnership, Risk, Boehringer Ingelheim, Royal Brompton Hospital, Patient, American Journal, Lung, WRVS, Biopharmaceutical, Biomarker, Vital capacity, American Thoracic Society, Idiopathic pulmonary fibrosis, IPF, Clinical trial, Tralokinumab, Idiopathic disease, FVC

The study was an analysis of AstraZeneca's Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF).

Key Points: 
  • The study was an analysis of AstraZeneca's Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF).
  • The patient data from the trial was processed with Brainomix's e-Lung tool.
  • The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
  • WRVS was also able to predict both short- and long-term outcomes of the patients, including lung function decline and survival.